Director/PDMR Shareholding

RNS Number : 3469Q

Mediclinic International plc

05 June 2018

 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

5 June 2018

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Vesting of awards under the Company's Forfeitable Share Plan

Awards of ordinary shares in Mediclinic (the "Shares") under the Mediclinic International Limited Forfeitable Share Plan ("FSP") granted in June 2015 vested on 1 June 2018.

The table below sets out the number of shares vested for Directors and other persons discharging managerial responsibilities ("PDMRs") who were granted awards under the scheme, together with any disposals made to satisfy their tax liabilities arising on vesting or for other reasons. Mr Danie Meintjes sold the minimum number of shares required to satisfy any tax liability arising on vesting. All shares were sold at a price of ZAR106.91 per Share.

Name	Director/ PDMR	Number of JSE Shares vested	Number of Shares sold	Number of Shares retained
Danie Meintjes	Director	33 949	15 786	18 163
David Hadley	PDMR	7 185	7 185	0
Gert Hattingh	PDMR	10 094	4,693	5 401
Koert Pretorius	PDMR	13 241	13 241	0
Dr Dirk le Roux	PDMR	5 828	5 828	0
Dr Ole Wiesinger1	PDMR	12 156	n/a	n/a

Notes:

1.     Dr Wiesinger was granted a conditional right to 12 156 Shares under the Country Schedule to the Forfeitable Share Plan in June 2015, receivable in cash or Shares on vesting, at Dr Wiesinger's option. On 1 June 2018, Dr Wiesinger elected to receive the equivalent value of the vested shares in cash.

The performance conditions for awards made under the FSP were tested following the change of control in Mediclinic International Limited, resulting from its reverse takeover of Al Noor Hospitals Group Plc. The corresponding awards vested on the original vesting date.

The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Daniël Petrus Meintjes
2.	Reason for the notification
a)	Position / status	Executive Director of the Company
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Vesting of award over ordinary shares granted under the Company's Forfeitable Share Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil cost 33 949
d)	Aggregated information Aggregated volume Price	33 949 Nil cost
e)	Date of the transaction	1 June 2018
f)	Place of the transaction	Johannesburg Stock Exchange
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Sale of shares vested under the Company's Forfeitable Share Plan to cover tax liabilities arising on vesting
c)	Price(s) and volume(s)	Price(s) Volume(s) ZAR 106.91 15 786
d)	Aggregated information Aggregated volume Price	15 786 ZAR 106.91
e)	Date of the transaction	1 June 2018
f)	Place of the transaction	Johannesburg Stock Exchange

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	David John Hadley
2.	Reason for the notification
a)	Position / status	Chief Executive Officer - Mediclinic Middle East
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Vesting of award over ordinary shares granted under the Company's Forfeitable Share Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil cost 7 185
d)	Aggregated information Aggregated volume Price	7 185 Nil cost
e)	Date of the transaction	1 June 2018
f)	Place of the transaction	Johannesburg Stock Exchange
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Sale of shares vested under the Company's Forfeitable Share Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) ZAR 106.91 7 185
d)	Aggregated information Aggregated volume Price	7 185 ZAR 106.91
e)	Date of the transaction	1 June 2018
f)	Place of the transaction	Johannesburg Stock Exchange

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Gert Cornelis Hattingh
2.	Reason for the notification
a)	Position / status	Chief Corporate Services Officer of the Mediclinic Group
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Vesting of award over ordinary shares granted under the Company's Forfeitable Share Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil cost 10 094
d)	Aggregated information Aggregated volume Price	10 094 Nil cost
e)	Date of the transaction	1 June 2018
f)	Place of the transaction	Johannesburg Stock Exchange
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Sale of shares vested under the Company's Forfeitable Share Plan to cover tax liabilities arising on vesting
c)	Price(s) and volume(s)	Price(s) Volume(s) ZAR 106.91 4 693
d)	Aggregated information Aggregated volume Price	4 693 ZAR 106.91
e)	Date of the transaction	1 June 2018
f)	Place of the transaction	Johannesburg Stock Exchange

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Koert Hendrik Stefanus Pretorius
2.	Reason for the notification
a)	Position / status	Chief Executive Officer - Mediclinic Southern Africa
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Vesting of award over ordinary shares granted under the Company's Forfeitable Share Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil cost 13 241
d)	Aggregated information Aggregated volume Price	13 241 ZAR 106.91
e)	Date of the transaction	1 June 2018
f)	Place of the transaction	Johannesburg Stock Exchange
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Sale of shares vested under the Company's Forfeitable Share Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) ZAR 106.91 13 241
d)	Aggregated information Aggregated volume Price	13 241 ZAR 106.91
e)	Date of the transaction	1 June 2018
f)	Place of the transaction	Johannesburg Stock Exchange

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Dr Dirk Cornelius le Roux
2.	Reason for the notification
a)	Position / status	Chief Information Officer of the Mediclinic Group
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Vesting of award over ordinary shares granted under the Company's Forfeitable Share Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil cost 5 828
d)	Aggregated information Aggregated volume Price	5 828 Nil cost
e)	Date of the transaction	1 June 2018
f)	Place of the transaction	Johannesburg Stock Exchange
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Sale of shares vested under the Company's Forfeitable Share Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) ZAR 106.91 5 828
d)	Aggregated information Aggregated volume Price	5 828 ZAR 106.91
e)	Date of the transaction	1 June 2018
f)	Place of the transaction	Johannesburg Stock Exchange

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Dr Thorsten Ole Wiesinger
2.	Reason for the notification
a)	Position / status	Chief Executive Officer - Hirslanden
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Vesting of award over ordinary shares granted under the Company's Forfeitable Share Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil cost 12 156
d)	Aggregated information Aggregated volume Price	12 156 Nil cost
e)	Date of the transaction	1 June 2018
f)	Place of the transaction	Johannesburg Stock Exchange

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

 

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

 

END

 

 

DSHGCGDLSUGBGIU